Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway

Leukemia Research

Volumn 34, Issue 8, 2010, Pages 1064-1069

  Königs, Sonja Katharina ^a   Pallasch, Christian Philipp ^a   Lindner, Lars Hartwin ^b,c   Schwamb, Janine ^a   Schulz, Alexandra ^a   Brinker, Reinhild ^a   Claasen, Julia ^a   Veldurthy, Aditya ^a   Eibl, Hansjoerg ^d   Hallek, Michael ^a   Wendtner, Clemens Martin ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

Alkylphospholipid; Apoptosis; CLL; Erufosine

Indexed keywords

ANTILEUKEMIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE INHIBITOR; ERUFOSINE; FLUDARABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOLIPASE A2; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LOW DRUG DOSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHOLIPASES A2; PHOSPHORIC ACID ESTERS; PROTO-ONCOGENE PROTEINS C-AKT; QUATERNARY AMMONIUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 77953613405     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.12.003     Document Type: Article

References (26)

1. Caligaris-Cappio F., Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999, 17:399-408.
2. Durig J., Nuckel H., Cremer M., Fuhrer A., Halfmeyer K., Fandrey J., et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003, 17:2426-2434.
3. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
4. Rassenti L.Z., Huynh L., Toy T.L., Chen L., Keating M.J., Gribben J.G., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
5. Nuckel H., Huttmann A., Klein-Hitpass L., Schroers R., Fuhrer A., Sellmann L., et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006, 47:1053-1061.
6. Oppezzo P., Vasconcelos Y., Settegrana C., Jeannel D., Vuillier F., Legarff-Tavernier M., et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005, 106:650-657.
7. Pallasch C.P., Schwamb J., Konigs S., Schulz A., Debey S., Kofler D., et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 2008, 22:585-592.
8. Zaharieva M.M., Konstantinov S.M., Pilicheva B., Karaivanova M., Berger M.R. Erufosine: a membrane targeting antineoplastic agent with signal transduction modulating effects. Ann N Y Acad Sci 2007, 1095:182-192.
9. Berger M.R., Tsoneva I., Konstantinov S.M., Eibl H. Induction of apoptosis by erucylphospho-N,N,N-trimethylammonium is associated with changes in signal molecule expression and location. Ann N Y Acad Sci 2003, 1010:307-310.
10. Fiegl M., Lindner L.H., Juergens M., Eibl H., Hiddemann W., Braess J. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol 2007, 1768:321-329.
11. van der Luit A.H., Budde M., Ruurs P., Verheij M., van Blitterswijk W.J. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 2002, 277:39541-39547.
12. Jendrossek V., Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents 2003, 3:343-353.
13. Noseda A., White J.G., Godwin P.L., Jerome W.G., Modest E.J. Membrane damage in leukemic cells induced by ether and ester lipids: an electron microscopic study. Exp Mol Pathol 1989, 50:69-83.
14. Jendrossek V., Muller I., Eibl H., Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 2003, 22:2621-2631.
15. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 1999, 59:2457-2463.
16. Kugler W., Erdlenbruch B., Otten K., Jendrossek V., Eibl H., Lakomek M. MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. Int J Oncol 2004, 25:1721-1727.
17. Handrick R., Rubel A., Faltin H., Eibl H., Belka C., Jendrossek V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 2006, 80:199-206.
18. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003, 14:167-173.
19. Kiss Z., Crilly K.S. Alkyl lysophospholipids inhibit phorbol ester-stimulated phospholipase D activity and DNA synthesis in fibroblasts. FEBS Lett 1997, 412:313-317.
20. Berkovic D., Luders S., Goeckenjan M., Hiddemann W., Fleer E.A. Differential regulation of phospholipase A2 in human leukemia cells by the ether phospholipid analogue hexadecylphosphocholine. Biochem Pharmacol 1997, 53:1725-1733.
21. Longo P.G., Laurenti L., Gobessi S., Sica S., Leone G., Efremov D.G. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
22. Seiffert M., Stilgenbauer S., Dohner H., Lichter P. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007, 21(9):1977-1983.
23. Hideshima T., Catley L., Yasui H., Ishitsuka K., Raje N., Mitsiades C., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.
24. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
25. Kolb J.P., Kern C., Quiney C., Roman V., Billard C. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 2003, 3:261-286.
26. Elter T., Borchmann P., Schulz H., Reiser M., Trelle S., Schnell R., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024-7031.